drug

COM503

1 story · latest Nov 9, 2026

Follow COM503. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Compugen Ltd

Timeline

Compugen completes enrollment in MAIA-ovarian trial of COM701, readout due Q1 2027

Nov 9Quarterly updateCOM701 Compugen Ltd

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.